Pre-operative platelet-bound CD40 ligand is probably associated with peri-operative cardiac events in hip and knee arthroplasty

European Journal of Clinical Investigation

Volumn 40, Issue 6, 2010, Pages 497-503

  Ray, Michael J ^a   Calabro, Lorenzo J ^a   Sirisena, Tilak ^b   Crawford, Scott A ^a   Crawford, Ross W ^c   Walters, Darren L ^b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b Prince Charles Hospital Laboratory Group Cardiology   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cardiac events; Platelet CD40 ligand; Total hip arthroplasty total knee arthroplasty

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; PADGEM PROTEIN; TROPONIN I;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVISED CARDIAC RISK INDEX; SCORING SYSTEM; THROMBOCYTE; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ARRHYTHMIAS, CARDIAC; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CD40 LIGAND; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEART DISEASES; HEART FAILURE; HUMANS; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; P-SELECTIN; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; TROPONIN I;

EID: 77952637058     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02289.x     Document Type: Article

References (29)

1. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system. Linking inflammation with atherothrombosis. J Am Coll Cardiol 2009 54: 669 677.
2. Henn V, Slupsky J, Grafes M, Anagnostopoulos I, Forster R, Muller-Berghaus G et al. CD40ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391: 591 594.
3. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001 98: 1047 1054.
4. Ray M, Crawford S, Crawford R, Jabur M, Walters D. Increased CD40 ligand expression on platelets is associated with cardiovascular events after total hip arthroplasty. J Thromb and haemost 2006 4: 695 697.
5. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990 72: 153 184.
6. Parvizi J, Johnson B, Rowland C, Ereth M, Lewallen D. Thirty-day mortality after elective total hip arthroplasty. J Bone Joint Surg Am 2001 83-A: 1524 1528. (Pubitemid 32953350)
7. Bolsin S, Colson M, Conroy M. Beta blockers and statins in non-cardiac surgery. BMJ 2007 334: 1283 1284.
8. Group PS, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.[see comment]. Lancet 2008 371: 1839 1847.
9. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.[see comment][erratum appears in J Am Coll Cardiol. 2008 Aug 26;52(9):794-7 Note: Chaikof, Elliott [corrected to Chaikof, Elliott L]]. J Am Coll Cardiol 2007 50: 1707 1732.
10. Lee T, Marcantonio E, Mangione C, Thomas E, Polanczyk C, Cook E et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999 100: 1043 1049.
11. Ridley S. Cardiac scoring systems-what is their value? Anaesthesia 2003 58: 985 991.
12. Borenstein M, Cohen J, Rothstein H, Schoenfeld D, Berlin J, Lakatos E. Power and Precision Version 2. London: Psychology Press, 2000. (ISBN 0805863257).
13. Shattil S, Cunningham M, Hoxie J. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987 70: 307 315.
14. Schmitz G, Rothe G, Ruf A. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998 79: 885 896.
15. Thygesen K, Alpert J, White H. Universal definition of myocardial infarction. J Am Coll Cardiol 2007 50: 2173 2195. (Pubitemid 350123680)
16. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005 96: 1365 1369.
17. Cuthbertson B, Amiri A, Croal B, Rajagopalan S, Alozairi O, Brittenden J et al. Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. Br J Anaesth 2007 99: 170 176. (Pubitemid 47249387)
18. Gibson S, Payne C, Byrne D, Berry C, Dargie H, Kingsmore D. B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery. Br J Surg 2007 94: 903 909.
19. Ackland GL, Scollay JM, Parks RW, de Beaux I, Mythen MG. Pre-operative high sensitivity C-reactive protein and postoperative outcome in patients undergoing elective orthopaedic surgery. Anaesthesia 2007 62: 888 894.
20. Heeschen C, Dimmeler S, Hamm C, van den Brand M, Boersma E, Zeiher A et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003 348: 1104 1111. (Pubitemid 36337321)
21. Choudhury A, Chung I, Panja N, Patel J, Lip GY. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. Chest 2008 134: 574 581.
22. Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci 2006 111: 341 347.
23. Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost 2000 84: 689 694.
24. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001 58: 4 43.
25. Garlichs C, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001 86: 649 655.
26. Cippolone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002 106: 399 402.
27. Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004 109: 1926 1929.
28. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005 111: 412 419.
29. Kinlay S, Schwartz G, Olsson A, Rifai N, Sasiela W, Szarek M et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004 110: 386 391.